Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rockwell Medical (RMTI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to 9.95%.

  • Rockwell Medical's EBITDA Margin fell 167800.0% to 9.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.37%, marking a year-over-year decrease of 69500.0%. This contributed to the annual value of 0.6% for FY2024, which is 85800.0% up from last year.
  • Latest data reveals that Rockwell Medical reported EBITDA Margin of 9.95% as of Q3 2025, which was down 167800.0% from 8.39% recorded in Q2 2025.
  • Rockwell Medical's EBITDA Margin's 5-year high stood at 6.84% during Q3 2024, with a 5-year trough of 54.52% in Q4 2021.
  • In the last 5 years, Rockwell Medical's EBITDA Margin had a median value of 9.95% in 2025 and averaged 18.39%.
  • In the last 5 years, Rockwell Medical's EBITDA Margin surged by 443400bps in 2022 and then tumbled by -167800bps in 2025.
  • Rockwell Medical's EBITDA Margin (Quarter) stood at 54.52% in 2021, then surged by 81bps to 10.18% in 2022, then surged by 76bps to 2.48% in 2023, then rose by 15bps to 2.1% in 2024, then crashed by -373bps to 9.95% in 2025.
  • Its EBITDA Margin was 9.95% in Q3 2025, compared to 8.39% in Q2 2025 and 7.19% in Q1 2025.